1. Introduction {#s0005}
===============

Rheumatoid Arthritis (RA) is an autoimmune disease and a systemic inflammatory disorder affecting joints and internal organs. It is one of the main causes of disability in the western world. The etiology and the triggers of autoimmunity and in particular of RA have been ascribed to different factors: genetic and environment. The humoral and cell-mediated immune responses in which self-reactivity plays an important role are key points in the pathophysiology of RA. The chronic synovial inflammation involved in joint destruction and disability is mediated by the infiltration of the activated immune cells: CD4 + T cells, B cells, dendritic cells and macrophages ([@bb0035], [@bb0225], [@bb0250], [@bb0155], [@bb0215]).

Family-based and twin-based studies have shown that the heritability of RA accounts for about 60% of the developmental risk, one third of which has been linked to two particular major histocompatibility antigens (human leukocyte antigens) namely HLA-DRB1\*04 and 01 ([@bb0045]). The genome-wide association studies (GWAS) and meta-analyses identified and combined a number of single nucleotide polymorphisms (SNPs) related to RA, both in HLA and non-HLA genes ([@bb0030], [@bb0150]). Several studies about the amino-acids motifs at the position 70--74 of the third hyper-variable region of HLA-DRB1 molecules associated not only with RA susceptibility (RR-QK-QRRAA as in DRB1\*0101, \*0102, \*0401, \*0404, \*0405, \*0408, \*0410, \*1001 and \*1402) or protection (DERAA as in \*0103, \*0402, \*1102, \*1103, \*1301, \*1302 and \*1304) ([@bb0055]), but also to disease severity and progression ([@bb0075]) with variations among different ethnicities and populations, also demonstrated in Kapitany et al. ([@bb0105]).

The response to (self or non-self) antigens restricted by similar class II MHC molecules leads to a usage of a limited number of rearrangements of the Beta chain of the TCR, shared among several patients, with common variable-diversity-junctional segments (V-D-J) and similar three-dimensional structures of the third complementarity-determining region (CDR3). Many studies have shown that in RA patients the TCR repertoire is skewed to certain BV genes, suggesting oligoclonal expansions ([@bb0235], [@bb0120], [@bb0245]) and phenotype alterations responsible of autoreactivity, immunosenescence and a proinflammatory state of CD4 + T lymphocytes ([@bb0205]). Such TCR repertoire remains stable during the disease, in part due to central tolerance that reduces the potentially self-reactive repertoire, and in part for competition between memory and naïve T cells in the lymph nodes for the antigen presentation ([@bb0110]).

Epitope encompassing residues 261--273 of type II human Collagen (CII~261-273)~ is the dominant antigenic epitope of Type II Collagen restricted by HLA DRB1\*04 and HLA DRB1\*01, as supported also by the observation that it is the dominant epitope for the T cell response during collagen-induced arthritis (CIA) in mice transgenic for the human HLA DRB1\*01 and DRB1\*04 in mice ([@bb0085]). Other studies demonstrated that the use of an altered peptide CII~261-273~ inhibits T cell activation in CIA induced mice ([@bb0260], [@bb0125]), and that T cell reactivity to the peptide 264--270 correlates with disease activity in a cohort of DRB1\*04 RA patients ([@bb0200]). Even though it has not been clarified if CII-specific T cells are involved in the pathogenesis of early RA or if they are a consequence of joint damage, the status or the size of the autoreactive T cell repertoire appears to be modulated by the level of both unmodified and glycosylated Collagen II peptides ([@bb0020]).

In a previous work ([@bb0180]) we performed a complete analysis of CDR3 length distribution of the TCR Vbeta-chain of T cells specifically expanded by Coll261-273 in HLA DRB1\*04^+^ ERA patients. We analyzed TCR BV gene usage and clonality of circulating and infiltrating T cells in the synovial fluid of RA patients using semiquantitative PCRs and modified BV-BJ immunoscope technique, finding that the repertoires of Coll~261--273~-specific T cells in peripheral blood and synovial fluid show a restricted variety of rearrangements of the TCR-beta chain. The TCR-beta chains identified by immunoscope analysis were sequenced and showed that identical aa sequenced were enriched by antigen stimulation among patients, and therefore identified a group of "shared" clonotypic, collagen-specific T cells. T cells carrying TRBV25-TRBJ2.2 were most frequently used among DR4 + patients affected by ERA. Finally, the majority of the repertoire was shared between different patients affected by RA ([@bb0180]) with respect to HLA DRB1\*04 + healthy controls. These results were confirmed through different methods in a small cohort of early and long standing RA patients, not selected on the basis of the HLA-DR([@bb0265]). When we investigated the mechanism of Coll~261-273~-HLA-DRB1\*04 recognition by TRBV domain using molecular modeling, protein-protein docking and molecular dynamics simulations, we could demonstrate that the residues 70--74 shared by HLA-DRB1\*01 and HLA-DRB1\*04 directly contributes to the engagement of beta chain of a Coll~216-273~-specific TCR ([@bb0040]).

In the present work, we aimed to define the association of the antigen specific T cell receptor with DR alleles, with disease activity-severity and with response to conventional DMARDs. The results show that the TRBV25 rearrangement identifies, along with HLA-DRB1, patients with the most active and refractory RA.

2. Material and Methods {#s0010}
=======================

2.1. Patients {#s0015}
-------------

A total of 90 patients affected by rheumatoid arthritis (RA) were enrolled, with symptoms duration of less than 12 months at diagnosis (ERA patients). Overall we collected 111 samples, 25 of which from ERA patients with a high disease activity (DAS ≥ 3.7), 31 with a DAS comprised between 3.7 and 2.4, 17 with a DAS between 2.4 and 1.6, and 38 samples from patients during a remission phase (DAS \< 1.6). All the recruited samples were prepared for the TCR analysis.

All the RA patients fulfilled the 1987 and 2010 American College of Rheumatology (ACR) criteria for RA ([@bb0015], [@bb0005]).

At baseline, ERA patients were treated with methotrexate (up to 20 mg weekly) and, when necessary, with a low steroid dosage for three months; a combination with a TNFα blocker (adalimumab 40 mg every two weeks, or etanercept 50 mg weekly) was started if patients did not reach at least a good response within three months from the onset of therapy, according to EULAR criteria (DAS44: DAS ≤ 2.4). ERA patients were followed every month up to three months and every three months thereafter. At each visit the ACR European League Against Rheumatism (EULAR) core data set (erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), swollen joint count (SJC), tender joint count (TJC), physician and patient global assessment, pain, health assessment questionnaire (HAQ)) was registered and DAS was calculated ([@bb0065]).

At each visit, clinical improvement and remission were evaluated according to DAS ([@bb0230], [@bb0165]). Written informed consent was obtained from all study subjects. This study was performed according to the Declaration of Helsinki and was approved by the local ethics committee.

2.2. HLA Genotyping {#s0020}
-------------------

We performed HLA-DRB1 genotyping and CDR3 length analysis in 90 ERA patients enrolled at different time points: 35 at diagnosis (T0), of which 20 with high disease activity (DAS ≥ 3.7), 12 with a moderate disease activity (3,7 \> DAS ≥ 2.4) and 3 with low disease activity (DAS \< 2.4); the other 55 patients also during the follow up of the disease (T ≠ 0) reaching a total number of 111 samples (for some patients more samples were collected at different time points). The mean disease duration since the enrollment of all the ERA patients was 10.7 months after diagnosis.

Genomic DNA for the HLA genotyping was obtained from whole blood of the 90 ERA patients using QIAamp DNA Mini kits for genomic DNA purification (Qiagen GmbH, Hilden, Germany) and 0.05--0.1 μg of purified gDNA were used for the PCR amplification of exon 2 of HLA-DRB1.

After PCR amplification molecular typing of HLA-DRB1 by a reverse hybridization method was performed using the INNO-LiPA HLA-DRB1 plus kit (Innogenetics N. V., Ghent, Belgium) and following manufacturer\'s instructions. Interpretation of hybridization of HLA-DRB1 probes was made by use of LiRAS software, to predict one digit HLA.

2.3. Cell Culture {#s0025}
-----------------

Peripheral blood mononuclear cells (PBMCs) were purified from whole blood by Lympholite-H density gradient (CEDARLANE Laboratories Ltd., Burlington, Canada), as described in manufacturer\'s protocol.

Purified PBMCs were cultured in presence or absence of 20 μg/ml Coll~261-273~ for 72 h in RPMI 1640 medium (Sigma Aldrich, St. Louis, MO, USA) supplemented with 2 millimoles/l [l]{.smallcaps}-glutamine, 50 millimoles/l of 2-ME (mercaptoethanol), 50 μg/ml of gentamicin (Sigma-Aldrich, St. Louis, MO, USA), and 1% human AB serum (following the protocol described in Nicolò et al. ([@bb0160]) and Ria et al. ([@bb0180])). Seventy-two hours later cells were harvested and antigen-specific cell proliferation was assessed by cell count after Trypan blue staining (Burker chamber). Cell death was shown not to be different between antigen-stimulated and unstimulated PBMC by staining for annexin V and Propide Iodide as described in our previous work ([@bb0180]) to avoid any bias.

2.4. Staining and Enrichment of IL-13 and IL-17-secreting T Cell {#s0030}
----------------------------------------------------------------

Coll~261-273~-specific T cells secreting IL-13 and IL-17 were stained and enriched from PBMCs obtained from ERA patients using MACS**®** secretion kit (Miltenyi Biotec, Germany) according to the manufacturer\'s instruction, following the protocols for enrichment of low-frequency secreting cells. Briefly, 2 × 10^7^ to 4 × 10^7^ cells obtained from PBMCs were stimulated in absence (background) or in presence of 10 μg/ml of Coll~261-273~ peptide (positive sample), in a 24-well plate at a concentration of 0.5 × 10^7^ cells ml/well. Three hours (for IL13 staining) and 16 h (for IL17 staining), cells were harvested and submitted to the staining procedure for each cytokine. The enrichment for cytokine-secreting cells was checked by flow cytometry (Coulter Epics FACS, equipped with Lysis software) (Beckman Coulter Inc., Fullerton, CA, USA) analysis. In order to evaluate correctly the number of antigen-specific cells, we examined by FACS 5 × 10^5^ cells both in the background and in positive samples. Total, negatively selected and positively selected cells were collected and prepared for mRNA isolation. As previously published ([@bb0160]), in order to prevent uncontrolled loss of mRNA due to scarcity of cells in the positively selected fraction (usually \~ 10^4^ total cells were recovered in the cytokine-positive fraction), mRNA obtained from 10^6^ TCR alpha-beta-BW cells (a mouse T cell line lacking the expression of alpha- and beta- chains of the TCR) was added to the positively selected cells before proceeding with mRNA isolation for the TCR repertoire analysis.

2.5. TCR Repertoire Analysis {#s0035}
----------------------------

Total mRNA was isolated from cell suspensions using RNeasy Mini Kit (Qiagen GmbH, Hilden, Germany), in accordance with the manufacturer\'s instruction. cDNA was synthesized using an oligo-dT primer (dT15; Gibco BRL Life Technologies). From each cDNA, PCR reactions were then performed. Sequences of TRBV25, TRBC1alfa and TRBJ2.2 specific primers were deduced from the IMGT (ImMunoGeneTics, [www.imgt.com](http://www.imgt.com){#ir0005}) and described in Ria et al. ([@bb0180]).

Using 2 μl of this product as a template, run-off reactions were performed with a single internal fluorescent primer for each BJ tested. These products were then denatured in formamide and analyzed on an Applied Biosystem 3130 Prism using Gene-mapper version 4.0 software (Life Technologies, Amsterdam, The Netherlands). Results are also reported as RSI (rate stimulation index = normalized peak area obtained from cells stimulated with antigen/normalized peak area of non-stimulated cells). Analyzing the 90 ERA patients we looked for TCRs expansions, in particular TRBV25-TRBJ2.2 with the length of 139 bases (alias name vb11-jb2.2, hereafter TRBV25). The cut-off for positive specific expansions defined as rate stimulation index (RSI) was settled RSI ≥ 1.8) and the TCRs sequences, identifying common variable-diversity-junctional segments (V-D-J), were described in our previous work ([@bb0180]).

We found on a large collection of samples that peaks of length other than those previously identified as associated with the response to Coll peptide had a SI of 1 ± 0.34 when ag − versus ag + were compared. Thus, we chose the SI value of 1.8 (\> average + 2SD) as a cut off value for a specific expansion.

2.6. Statistical Analysis {#s0040}
-------------------------

Data were analyzed using SPSS Statistics 20.0 (IBM Corp., Armonk, NY, USA) and Prism software 6.01 (Graph-Pad, San Diego, CA 92121-USA). Categorical and quantitative variables were respectively described as numbers, percentages (%) and mean ± standard deviation (SD). Mann--Whitney\'s test was used to compare continuous variable. Categorical variables were analyzed using χ2 test or Fisher\'s test, depending on sample size restrictions. Kaplan--Meier survival plots were created using Prism software 6.01 (Graph-Pad, San Diego, CA 92121-USA). Statistical significance of survival analyses and P-values were determined by applying the Log-rank statistical method (Mantel-Cox test) and the Gehan--Breslow method (Wilcoxon test) taking into account multiple comparisons. A value of P \< 0.05 was considered statistically significant.

3. Funding {#s0045}
==========

This work was partially supported by "linea D1" from Catholic University of Rome (Gianfranco Ferraccioli and Francesco Ria).

4. Results {#s0050}
==========

4.1. HLA-DRB1 and Disease Activity at Diagnosis: Group Differences {#s0055}
------------------------------------------------------------------

We examined in our cohort whether DR4-4, DR4-11 and DR4-1 patients represented collectively a subgroup of patients with a more aggressive disease.

A total of 90 ERA patients treated with the treat-to-target strategy were enrolled. The mean DAS value in the whole ERA cohort was 3.8 ± 1.1 (51.1% with an active disease-DAS ≥ 3.7, 42.2% with a moderate disease-2.4 \< DAS \< 3.7 and 6.7% with a low disease activity-DAS ≤ 2.4). The demographic, immunological and clinical characteristics of RA patients are shown in [Table 1](#t0005){ref-type="table"}.

The HLA-DRB1 genotyping of ERA patients showed, as expected ([@bb0175], [@bb0185]), a high prevalence of HLA DRB1\*04 and \*01 positive patients ([Supplementary Fig. 1](#f0030){ref-type="fig"}a). The allelic frequency of DR4 was 18.9% in a total of 27 out 90 ERA patients, of which 7 (7.8%) were homozygous; moreover, the allelic frequency of DR1 + was 13.3% in a total of 21 subjects, of which 3 (3.3%) were homozygous and 5 (5.6%) were DR4 + DR1 +. Finally, the allelic frequency of DR11 was 18.3% for a total of 32 out 90 ERA patients, of whom 2 (6.3%) were DR1 + DR11 + and 4 were DR4 + DR11 + (12.5%). ([Table 2](#t0010){ref-type="table"}) Thus, DR11, despite its protective role in RA, appears to be the second most frequent allele in this cohort of patients ([Supplementary Fig. 1](#f0030){ref-type="fig"}a and [Table 2](#t0010){ref-type="table"}), and for this reason we decided to examine in depth its association to RA.

We did not consider the alleles with a frequency less than 10% because the low number of cases was not sufficient to do a correct power analysis. Nevertheless, in our cohort of ERA DR3, DR7, DR8, DR9, DR10, DR12, DR14, DR15 and DR16 seemed not to be involved in RA characteristics (severity or outcome). DR13 allele (13.5%) in our cohort of RA did not associate with the clinical parameters-data and was not considered into the analysis, also on the basis of its known protective role in RA ([@bb0140]).

We examined whether the presence of isolated DR4, DR1 and DR11 had any effect on severity of the disease at diagnosis. Data reported in [Fig. 1](#f0005){ref-type="fig"}a show that the individual presence of each of these DR alleles per se did not associate with the severity of the disease at diagnosis. Next, we focused our analysis on the 27 DR4 + patients only, and we observed that patients homozygous for HLA-DRB1\*04 or carrying HLA-DRB1\*01 or HLA-DRB1\*11 as the second allele showed a higher disease activity at diagnosis when compared to DR4^+^ patients carrying other HLA-DRB1 alleles, both when DAS was divided in classes (data not shown *p* = *0.03*) and when the absolute value of DAS was considered ([Fig. 1](#f0005){ref-type="fig"}b, 4.3 ± 1.4 vs 2.9 ± 0.6, *p* = 0.002).

4.2. DR Haplotype and Disease Activity Determine the Presence of Circulating Coll263-271-specific *TRBV25* + T Cells {#s0060}
--------------------------------------------------------------------------------------------------------------------

Next, we examined the possible relationship between disease activity score and the presence and/or level of stimulation index of T cells carrying the shared *TRBV25* rearrangement in DR4 + patients. Patients were divided in low (n = 11) or moderate-high activity (n = 16) on the basis of their DAS at the moment of the test. We found expansions of the huColl~261-273~ specific TCR rearrangement of interest (TRBV25-TRBJ2.2 with a length of 139 base pairs) more frequently in patients with a moderate-high disease activity score than in patients with a DAS \< 2.4. In DR4 + ERA patients, DAS seemed to be directly proportional to the absolute value of the RSI (data not shown, p = 0.01) and this was confirmed by the comparison of the two groups of patients (low versus moderately-highly active disease) on the basis of positivity (RSI ≥ 1.8) versus negativity (RSI \< 1.8) of *TRBV25*; eleven out of sixteen (68.8%) patients with a moderate-high disease activity were positive for *TRBV25* + cells versus one out of eleven (9.1%) patients with a DAS \< 2.4 (p = 0.0047, exact Fischer\'s test, [Fig. 2](#f0010){ref-type="fig"}a).

Next we examined if the second HLA allele had an influence on the presence of cells carrying the *TRBV25* TCR within the DR4 + group of patients. [Fig. 2](#f0010){ref-type="fig"}b reports the RSI of the *TRBV25* rearrangement and the DAS value for each of the DR4 + patients examined (n = 27), with the different symbols representing the second DR allele. Thus, on a total of 11 DR4 + ERA patients that used the collagen-specific *TRBV25* rearrangement, we observed that 4 were DR4 + DR11 +, 4 were homozygous for DR4, and 1 was DR4 + DR1 +. All these patients were examined when in high or moderate disease activity. Intriguingly, all DR4 + DR11 + patients grouped within the samples obtained during moderate-high disease activity and positive for *TRBV25* usage, while some patients homozygous for DR4 or having DR1 as the second DR allele fell in the group of DR4 + ERA patients with high or moderate disease activity, not using the collagen-specific *TRBV25* rearrangement. Thus, it appears that DR11 allele is able to promote the usage of *TRBV25* by DR4 + subjects at least as well as (and possibly even better than) a second DR4 allele. Finally, the vast majority (8/11) of DR4 + patients with a low disease activity at the moment of the test were heterozygous, but having as a second DR allele DRs different from DR1 or DR11 ([Fig. 2](#f0010){ref-type="fig"}b).

Overall, these results, despite the low number of patients, suggest that the presence of peripheral blood T cells carrying the TRBV25 TCR specific for Coll261-273 represent a marker of moderate-high disease activity in RA patients carrying DR4 allele. Moreover, the homozygosity for DR4 or the combination of DR4 with DR1 or, surprisingly, with DR11 seems to be associated with the usage of Coll261-273 specific T cells, carrying the TRBV25 TCR, and with increased disease severity and resistance to therapy.

4.3. HLA-DRB1 Haplotype Predicts Response to Therapy in ERA Patients {#s0065}
--------------------------------------------------------------------

Since we had observed that HLA was associated with disease activity at the onset and with selection of a TCR repertoire in the DR4 + group of patients, next we examined the influence of HLA-DR on the therapeutic outcome of the patients. Overall, 60 (58.8%) ERA patients were classified as good EULAR responders, while 38.8% and 50.6% were in DAS remission (DAS \< 1.6) at 6 and 12 months follow-up visit, respectively. Five ERA patients were lost during follow-up. Results are reported in [Fig. 3](#f0015){ref-type="fig"}a and b. Following the results reported in the above section, we divided patients in 4 groups: Group 1: DR4, DR1 and DR11 triple negative; Group 2: DR4- and DR1 + or DR11 +; Group 3: DR4 + and DR1- or DR11-; Group 4: DR4 + in combination with another DR4 or a DR1 or DR11. Patients belonging to Group 1 and 3 were more frequently good responders if compared to patients of Group 2 and of Group 4.

DR4 + ERA patients having DR1, DR4 or DR11 as a second allele received a combination therapy with biologic agents within 12 months follow-up (73.3%). This finding was significantly higher compared to RA patients of other groups at the same time point of follow up (nearly 30.0%; p = 0.002) ([Fig. 3](#f0015){ref-type="fig"}c and [Supplementary Fig. 2](#f0035){ref-type="fig"}). However, in terms of outcome of the combination therapy of patients of group 4, compared to that of patients belonging to the other groups submitted to the same therapeutic regimen, no differences could be observed ([Fig. 3](#f0015){ref-type="fig"}d).

Taken together, these data indicate that a DR4-4, DR4-1 or DR4-11 genotype marks a group of patients suffering a more active and severe disease, which appears resistant to DMARDs but responsive to biologic therapy.

4.4. HLA-DRB1 and Seropositivity for ACPA are Complementary in Identifying the Subsets of Good and Poor Responders {#s0070}
------------------------------------------------------------------------------------------------------------------

We wondered whether the combination of HLA DR alleles associated with severity of disease was simply highlighting the same population of RA patients showing presence of anti-cyclic citrullinated peptide antibodies. Thus, we separated our ERA patients cohort into ACPA + (seropositive) and ACPA- (seronegative) and, as done in [Fig. 4](#f0020){ref-type="fig"}, divided them into 4 subsets: Group 1: DR4, DR1 and DR11 triple negative; Group 2: DR4- and DR1 + or DR11 +; Group 3: DR4 + and DR1- or DR11-; Group 4: DR4 + in combination with another DR4 or a DR1 or DR11.

First, we noticed that ACPA + ERA patients (n = 66) with expanded *TRBV25* + T cells are more frequent in the group 4 (6 out 13, black circles, [Fig. 4](#f0020){ref-type="fig"}a and b). When we compared the response to therapy in seropositive patients, groups 1 (n = 13), 2 (n = 31) and 3 (n = 9) were frequently good responders; they could gain an early DAS reduction of at least 1.2 and a DAS \< 1.6. ACPA + DR4 + ERA patients with DR4, DR1 or DR11 as second DR allele (group 4, black line), on the other hand, presented a poor response to a treat to target strategy with remission significantly delayed ([Fig. 4](#f0020){ref-type="fig"}c) and they were treated significantly more often with biologic DMARDs therapy ([Fig. 4](#f0020){ref-type="fig"}e) than the other groups. Thus, having a DR4-4, DR4-1 and DR4-11 allele combination represents a marker of poor response to therapy also when examined within the ACPA + group of ERA patients.

ACPA- ERA patients (n = 24) seem to have a different response to a treat to target strategy, but numbers are too small to predict a significantly different outcome ([Fig. 4](#f0020){ref-type="fig"}d and f). Overall DR and ACPA appear complementary tools to identify good and poor responders.

4.5. Cells Carrying TRBV25 can Produce IL-17 {#s0075}
--------------------------------------------

We have shown above that the same HLA-DRB1 haplotype predicts severity of the disease and resistance to treatment and in parallel usage of TRBV25 collagen-specific T cells, which are also associated with a more severe outcome of the disease. This observation leads to the hypothesis that an effect of HLA-DRB1 haplotype is the selection of collagen specific T cells characterized by higher aggressive behavior. An important goal to better investigate the role of T cells in RA is the characterization of their cytokine production, in particular IL17 and IL13. As a proof of concept here we report two case-reports where we explored the hypothesis of this connection. We stimulated PBMC from 2 DR4 + ERA active patients with Coll~261-273~ and sorted the T cells secreting IL17 and IL13. We examined the presence of T cells specific for huColl~261-273~ using the VB-JB pairs previously shown to host shared TCR-beta chain rearrangements. The RA patients presented in the PBMC 7 TCR-beta chains that were expanded by the stimulation with huColl~261-273~, among which there were the shared *TRBV25* T cells (CDR3 length of 139 bases and Rate Stimulation Index of 1.8). When we examined the presence of the same 7 TCR-beta chain rearrangements found in the blood in the IL17-secreting cell population, we could detect only the *TRBV25* TCR chains ([Fig. 5](#f0025){ref-type="fig"}a). Thus, the antigen specific T cells able to secrete IL17 seem to represent a restricted subpopulation within the total T cell repertoire responding to the self-antigen during the acute presentation of the disease ([Fig. 5](#f0025){ref-type="fig"}b). The *TRBV25* rearrangement was not enriched in the IL-13 secreting population from the same patients, nor from PBMC IL17^+^ or IL13^+^ T cell populations in two more patients in low disease activity (data not shown) further suggesting that its presence may be involved in the activity of the disease.

5. Discussion {#s0080}
=============

RA has long been considered an autoimmune disease, in which immune complexes mediate tissue injury ([@bb0240], [@bb0100]). The failure to correlate disease activity to the levels of autoantibodies and the realization that RA exists in individuals not expressing RF, suggest that T cell very likely play a major role through T cell-dependent effector mechanisms and T cell-derived cytokines, released upon T cell recognition of Ag in the synovial membrane ([@bb0060], [@bb0270]). Activation of macrophages and synovial fibroblasts causes the formation of a tissue-invasive pannus.

HLA-D, expressed by antigen presenting cells (APCs), hosts in the peptide-binding groove the antigenic fragments to present to T cell receptor (TCR) on cognate T cells. The polymorphisms of HLA-D molecules can change the amino-acid side chains of the binding pockets, altering the TCR-peptide-HLA-D interface. For example the residues at positions 11, 71 and 74 of the HLA-DRB1 chain are associated with the higher RA susceptibility in HLA-DRB1\*0401 and \*0404, while the \*0402 allele has a protective role ([@bb0080], [@bb0210], [@bb0130]).

Our data confirm the link between HLA-DRB1 and RA and in particular in our cohort of 90 Italian patients as expected a 44 present DR4 and/or a DR1 allele, but the second most frequent allele is DR11, despite in literature it is described as having a protective role in RA. It is not the first observation of an HLA allele with controversial role: in the case of HLA-DRB1\*13 allele, it has been described an association with increasing risk of RA development when in combination with DRB1\*03 and in ACPA negative patients, and at same time a protecting role in ACPA positive patients ([@bb0140]); similarly DR11 seems to have a "janus" effect in RA, in particular modulated by the association with DR4.

A modification of the selection of self-epitopes by simultaneous presence of two HLA alleles may be one mechanism that explains this "janus" effects. As demonstrated in other autoimmune models, the modification of peptide presentation can result in the promotion of positive selection of pathogenic autoreactive thymocytes and/or in the failure to trigger their subsequent deletion; moreover protective class II molecules would select a repertoire of T-cells endowed with decreased pathogenicity ([@bb0135]). The disease predisposing class II MHC molecules have also been suggested to contribute to autoimmune inflammation by modulating the cytokine production of T lymphocytes in the peripheral tolerance homeostasis ([@bb0145]). Protective class II MHCs have been proposed to compete against or to interfere with self-antigen presentation for capture of determinants ([@bb0050], [@bb0070]). In this context it has been demonstrated that pathogenic autoreactive TCRs are "MHC-promiscuous" ([@bb0190]), evidence derived from the fact that individual TCRs have the inherent potential to recognize a wide set of peptides embedded in a single MHC molecule or multiple MHC molecules presenting the same or different peptides ([@bb0255], [@bb0025]).

A further role of the protective class II molecules in autoimmune disease resistance could be related to the modulation of T regulatory cells against the self-reactions ([@bb0220]).

The restriction of the TCR and the sharing of T cells among different Germinal Centers strongly support a role for few antigens driving the formation of tertiary lymphoid tissue and subsequent tissue destruction in the rheumatoid joint ([@bb0220]).

These antigens are obviously shared among patients because the follicular CD4 T cell clones undergo stimulation in the autologous as well as in the heterologous tissues. The restriction to HLA-DRB1 molecules is in line with the recognition of classical peptide antigens.

In the present report, we demonstrate that the already known biomarker of severity DRB1 (it associates with seropositivity and erosions) also associates with circulating T cells specific for Coll261-273. These cells using the shared TCR-beta chains TRBV25-TRBJ2.2 (alias VB11-BJ2.2) are significantly associated with disease activity in the group of DR4 + RA patients, and with a worse outcome. The relevance of the antigen-specific T helper cells has been recently confirmed and their analysis could represent a new possible approach in the evaluation of RA ([@bb0195]). Furthermore it has been demonstrated that HLA-DRB1\*04 contributes to RA risk, specifically in CD4 + T cells, with a cognate and continuous stimulation of TCR-CD3 complexes that culminates in intracellular signaling able to increase the NF-κB activity and to promote a proinflammatory state ([@bb0205]). Thus, we propose that the usage of this T cell receptor is able to predict the outcome of the disease in DR4 + patients ([@bb0060], [@bb0170], [@bb0010]) and even if it seems to involve a portion of RA patients, we show here that this subgroup presents a delayed remission. Probably one of the main reasons is that DMARDs therapy after diagnosis, as indicated by the treat to target strategy, is insufficient and only biological treatment is useful for them; in this sense a TCR specificity in combination with HLA appears to lead to a more aggressive therapy since the beginning.

Previous works from other groups have demonstrated that homozygosity for alleles of the DR predisposes to RA severity ([@bb0140]). Here we confirm this observation and report for the first time that also heterozygosity for DR4-DR1 and DR4-DR11 associate with a more severe disease. Interestingly, this role of DR11 as a predictor of worse disease is limited to the DR4 + and ACPA positive RA patients, while no effect of DR11 per se could be observed in the whole cohort of RA patients.

Heterozygosity of DR4-DR11 and, to a lesser extent, DR4-DR1 and homozygosity for DR4, are associated with the presence of TRBV25-TRBJ2.2 +, collagen-specific T cells during the acute presentation of the disease. As a proof of concept of our hypothesis we show here that TRBV25-TRBJ2.2 + T cells likely secrete IL-17, thus contributing to the aggressiveness of the disease ([@bb0115], [@bb0090]). Thus, these data suggest that these allelic combinations may promote the selection of T cells primed for the collagen-specific self-reactive response and with possible polarization to a milieu much more inflammatory ([@bb0160]).

6. Conclusions {#s0085}
==============

In the present work, we hypothesize that autoreactive T cells, could be selected on the background of DR4-DR1-DR11 as second alleles in the DR4 + RA patients (enhancing the differentiation of autoreactive T cells) leading to detect the subgroup of patients with a more severe presentation of RA and a marked resistance to DMARDs. The analysis of the HLA-DRB1 (determination of the HLA DRB1\* is a test available in most hospital centers) and of T cells specific for Coll~261-273~ carrying the shared *TRBV25-TRBJ2.2* rearrangement can be proposed as a possible biomarker matrix that identify those RA patients who will not satisfactorily respond to treatment following a treat to target strategy with TNFα blockers.

Prospective studies stratifying the patients at diagnosis will be necessary. We are aware of the limits of our cohort, diverse numbers in different subsets, heterogeneity of the genetic background, different therapies at follow-up, yet all the data move into the same direction: our study shows that the analysis of collagen specific the T cell repertoire, of HLA-DR and seropositivity appear complementary tools to identify the best and the poorest responders to DMARD therapy in a treat to target strategy. Therefore the study offers some clues to predict the course in terms of a personalized treatment in RA patients ([@bb0095]).

The following are the supplementary data related to this article.Supplementary Fig. 1HLA-DRB1 frequency and demographic, immunological and clinical characteristics of ERA patients at the study entry. (a) The bars chart shows the allelic frequency of HLA-DRB1 alleles in the 90 ERA patients cohort. The corresponding population of reference is the central Italy where the allelic frequencies of the most represented alleles of the cohort are different (7.4% for DR1, 8.2% for DR4, 27% for DR11 and 10.5% for DR13). The source of Italian allelic frequency is the database [www.allelefrequencies.net](http://www.allelefrequencies.net){#ir0010}. (b) Values are mean ± standard deviation unless otherwise indicated. ERA: early rheumatoid arthritis; ACPA: anti-citrullinated peptide antibodies; RF: rheumatoid factor; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; TJC: tender joint count; SJC: swollen joint count; DAS: disease activity score; HAQ: Health Assessment Questionnaire. ACPA, RF, ESR, CRP, TJC, SJC and HAQ are missing in 6 patients.Supplementary Fig. 2Response to anti-TNF therapy. ERA patients are evaluated twelve months (T12) after study entry during treat to target therapy, in terms of percentage of subjects who were under a biologic treatment; they are displayed in 4 groups on the basis of the allelic combination: 1) DR4, DR1, DR11 triple negative (white bars), 2) DR4-and DR1 + or DR11 + (bright gray bars), 3) DR4 + and DR1- or DR11- (dark gray bars) and 4) DR4 allele in combination with another DR4 or a DR1 or DR11 (black bars). Patients of the group 4 were treated significantly more often with anti-TNF therapy than group 1 (\*p = 0,05) and than group 3 (°p = 0,03).Supplementary material.
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![HLA DRB1 is associated with disease severity at the onset in DR4 + patients. (A) The six groups of patients positive or negative for HLA-DRB1\* allele 01, 04 and 11 are divided in 3 classes, based on DAS at onset: DAS ≤ 2.4 (white), 2.4 \< DAS \< 3.7 (gray) and DAS ≥ 3.7 (black). (B) DR4 + patients (N = 27) were divided in two groups on the basis of the second DRB1\* allele: all the DR4 + patients are shown individually on the basis of DAS at the onset and on the basis of the presence (black circles) or the absence (white circles) of DR4 or DR1 or DR11 as second allele. Each group is further subdivided, as described for panel A.](gr1){#f0005}

![TRBV25 usage and DR4 and DR11 are markers of disease activity and of response to "treat to target" strategy. (a) PBMC from 27 consecutive HLA DRB1\* 04 + ERA patients at different phases of disease activity were stimulated with Coll~261-273~ and considered positively expanded when rate stimulation index (RSI) of TRBV25 was at least 1.8 or superior. The DR4 + patients, samples positive for the usage of shared TCR (here represented in percentage) are significantly more frequent in subjects with higher DAS. P value is evaluated with unpaired non-parametric Mann Whitney\'s test comparing patients on the basis of TRBV25 positivity and negativity (p = 0,04). (b) Associations between DAS, RSI for TRBV25 + cells and the second HLADRB1\* allele in the 27 DR4 + ERA patients. Vertical dashed lines indicate DAS of 1.6, 2.4 and 3.7. Symbols indicate patients homozygous for DR4 (gray circles), or DR4/1 (white circles), DR4/11 (black circles) and finally those in which DR4 was associated with any other HLA allele (white squares).](gr2){#f0010}

![DR1, DR4 and DR11 allele combinations and the outcome of disease activity. (a) ERA patients are evaluated after six (T6) and twelve (T12) months of follow up during treat to target therapy and are displayed in 4 groups on the basis of the allelic combinations: 1) DR4, DR1 and DR11 triple negative (white bars), 2) DR4- and DR1 + or DR11 + (light gray bars), 3) DR4 + and DR1- or DR11- (dark gray bars) and 4) DR4 allele in combination with another DR4 or DR1 or DR11 (black bars). Patients\' outcome is reported using EULAR criteria for good response (DAS reduction ≤ 1.2 left bars) or for the achievement of a DAS value \< 1.6 (right bars). Patients in group 4 show a significant poorer response to treatment (unpaired non-parametric Mann Whitney\'s test, T6 p = 0.04 (\* 4 versus 1, ° 4 versus 2, \# 4 versus 3): T12 \* p = 0.03 and ° p = 0.05. (b/c/d) Cumulative Kaplan Meyer plots of the same groups of patients described in (a) (Group 1, dashed gray; Group 2, dashed black; Group 3, continuous gray; Group 4, continuous black) indicating (b) the % of patients not in remission (DAS \< 1,6 and DAS variance \> 1.2) of the disease, (c) the % of patients not adding biologic treatments and (d) % of patients not in remission after addition of biologic therapy. The p values were evaluated with Log Rank (Mantel Cox\'s test) and ERA patients of group 4 showed a behavior significantly different for time to remission (b) p = 0.03 and for time to addition of biologic treatment (c) p = 0.002, but not for time of remission after addition of biologic therapy (d) p = 0.2.](gr3){#f0015}

![DR1, DR4 and DR11 allele combinations and the outcome of disease activity in ACPA positive patients. ERA patients are divided on the basis of the positivity to ACPA (ACPA +, a, c, e) and ACPA- (b, d, f) and are divided in the 4 groups described in [Fig. 3](#f0015){ref-type="fig"}, on the basis of the allelic combinations. ACPA statuses are missing in 5 patients. (a and b) Correlation between ACPA positivity, DR and RSI of the Coll~261-273~-specific TRBV25 + T cells (number of patients per group: ACPA + = 66 distributed in 1A = 13, 2A = 31, 3A = 9, 4A = 13; ACPA- = 24 divided in 1B = 8, 2B = 11, 3B = 3, 4B = 2). (c to f) Cumulative Kaplan Meyer plots of the same groups of patients divided according to DR as already described in [Fig. 3](#f0015){ref-type="fig"} (BD) (Group 1, dashed gray; Group 2, dashed black; Group 3, continuous gray; Group 4, continuous black) indicating (c, d) the % of patients not in remission (DAS \< 1,6 and DAS variance \> 1.2) of the disease, (e, f) the % of patients not yet adding biologic treatments. Missing patients for follow up data are 14 for C, 9 for D and 10 for E and F, P values of Kaplan Meyer plots are evaluated with Log Rank (mantel Cox\'s test) and patients of Group 4 had a significantly worse outcome than the other groups in the ACPA + patients: p = 0.01 for c, p \< 0.0001 for e.](gr4){#f0020}

![TRBV25 + cells are enriched among T cells secreting IL17 after stimulation with Coll~261-273~ during active presentation of disease. PBMC from DR4 + patients during moderate disease activity phase (a, DAS = 2.6) or low disease activity (b, DAS = 1.3) were cultured in presence of Coll~261-273~ and magnetically sorted for secretion of IL17 (left panels) or IL13 (right panels). For each patient, the presence of a Coll~261-273~-driven expansion of T cells was examined after 72 h of culture in the absence or presence of the peptide antigen (middle panels). All panels report the distribution of CDR3-beta peaks obtained by Immunoscope analysis of rearrangement TRBV25-TRBJ2.2. The black peak corresponds to the length of 139 bases that identifies the shared Coll~261-273~-specific rearrangement. This peak appears enriched only in IL-17 secreting cells obtained from the patient in a moderate disease activity phase (a).](gr5){#f0025}

###### 

Demographic, immunological and clinical characteristics of ERA patients at diagnosis. Values are mean ± standard deviation unless otherwise indicated. ERA: early rheumatoid arthritis; ACPA: anti-citrullinated peptide antibodies; RF: rheumatoid factor; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; TJC: tender joint count; SJC: swollen joint count; DAS: disease activity score; HAQ: Health Assessment Questionnaire. HLA: histocompatibility Leucocyte Antigen. ESR, CRP, TJC, SJC, HAQ, are missing in 5 patients.

                                 ERA patients
  ------------------------------ --------------
  N.                             90
  Age, (years)                   55.0 ± 13.6
  Sex, n° female, (%)            70.0 (77.8)
  ACPA \> 5 U/ml n. (%)          64 (71.1)
  RF-IgM \> 20 U/ml n. (%)       46 (51.1)
  ESR (mm/1 h)                   41.9 ± 26.4
  CRP (mg/l)                     24.9 ± 31.7
  TJC                            11.6 ± 8.0
  SJC                            14.7 ± 8.8
  DAS                            3.8 ± 1.1
  HAQ                            1.29 ± 0.77
  Symptoms\' duration (months)   6.27 ± 3.55
  HLA-DRB1\*01 n. (%)            21 (23.3)
  HLA-DRB1\*04 n. (%)            27 (30.0)
  HLA-DRB1\*11 n. (%)            32 (35.6)

###### 

HLA-DRB1\*01, \*04 and \*11 alleles. Values report the absolute number of positive subjects and frequency (%) in the 90 ERA patients, for each indicated haplotype.

  ERA patients (N = 90)                                                                                
  ------------------------------------------- ----------- -------------- -------------- -------------- ---------------------------
  HLA-DR allele combinations                  n\. (%)     HLA-DRB1\*01   HLA-DRB1\*04   HLA-DRB1\*11   Other allele combinations
  HLA-DRB1\*01                                21 (23.3)   3 (3.3)        5 (5.6)        2 (2.2)        11 (12.2)
  HLA-DRB1\*04                                27 (30.0)   5 (5.6)        7 (7.8)        4 (4.4)        11 (12.2)
  HLA-DRB1\*11                                32 (35.6)   2 (2.2)        4 (4.4)        \-             26 (28.9)
  HLA-DRB1\*04 + and (04 + or 01 + or 11 +)   16 (17.8)                                                
